Eisai Co Ltd (ESALF) 65.6135 $ESALF
Cognitive Impairment - Pipeline Review, H1 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z64d6n/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Dart NeuroScience LLC - Eisai Co., Ltd. - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Iproteos S.L. - Merck & Co., Inc. - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - Neuralstem, Inc. - Novartis AG - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - Sanofi - Shire Plc - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Upsher-Smith Laboratories, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/z64d6n/cognitive
PFE: 33.99 (unch), LLY: 72.76 (-0.14), BMY: 67.76 (+0.12), AZN: 68.79 (-0.50), MRK: 60.24 (+0.01), SHPG: 255.26 (+0.81), TEVA: 59.98 (-0.25), ABBV: 65.30 (-0.69), CUR: 1.69 (-0.01), NVS: 104.05 (+0.30)
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting
JCN Newswire - Thu May 14, 2:12AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that a series of abstracts highlighting new study results on Halaven (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, "eribulin" and Lenvima (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib" will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
Medullary Thyroid Cancer Therapeutics Clinical Trials Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 30, 6:31AM CDT
The report "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. Complete report on H1 2015 Clinical Trials review of "Medullary Thyroid Cancer" addiction with 44 market data tables and 109 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/medullary-th...eport.html .
IMMU: 4.15 (+0.03), EXEL: 3.34 (-0.03)
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies
JCN Newswire - Mon Apr 27, 8:32AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, "Eisai" and Nihon Medi-Physics Co., Ltd. (Headquarters: Tokyo, Representative Director, President: Dr. Yutaka Takeuchi, "Nihon Medi-Physics" announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan.
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 7.48 (+0.14), FOMX: 11.49 (+0.08), GSK: 44.58 (-0.19), BMY: 67.76 (+0.12), CBPO: 102.28 (+0.72), DERM: 14.90 (-0.07), CCXI: 8.03 (+0.82), ANAC: 61.04 (-1.33), CLTX: 0.55 (unch), CELGZ: 2.60 (-0.10)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 12.57 (-0.09), GSK: 44.58 (-0.19), CELGZ: 2.60 (-0.10)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 12.74 (-0.02), FOMX: 11.49 (+0.08), PVCT: 0.87 (unch), JNJ: 102.46 (+0.16), DERM: 14.90 (-0.07), ANAC: 61.04 (-1.33), XNCR: 15.44 (+0.12), REGN: 488.41 (-0.60), AQXP: 7.48 (+0.14), BMY: 67.76 (+0.12), GSK: 44.58 (-0.19), VRX.TO: 270.02 (+2.67), CBPO: 102.28 (+0.72), MRK: 60.24 (+0.01), CCXI: 8.03 (+0.82), CLTX: 0.55 (unch), CELGZ: 2.60 (-0.10), NVS: 104.05 (+0.30)
CNS Therapeutics - Global Strategic Business Report 2015-2020
M2 - Mon Apr 13, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht282w/cns_therapeutics) has announced the addition of the "CNS Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 145 companies including many key and niche players such as: - AbbVie Inc. (USA) - Actavis Plc. (Ireland) - Alkermes Plc. (Ireland) - Amneal Pharmaceuticals, LLC (USA) - Aspen Pharmacare Holdings Limited (Australia) - AstraZeneca Plc (UK) - BIAL Group (Portugal) - Boehringer Ingelheim GmbH (Germany) - Bristol-Myers Squibb (USA) - Dainippon Sumitomo Pharma Co., Ltd. (Japan) - Eisai Co., Ltd. (Japan) - Eli Lilly and Co. (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fabre-Kramer Pharmaceuticals, Inc. (USA) - GlaxoSmithKline (UK) - H. Lundbeck A/S (Denmark) - Johnson & Johnson (USA) - Janssen Pharmaceuticals, Inc. (USA) - Merck & Co., Inc. (USA) - Neurocrine Biosciences, Inc. (USA) - Novartis AG (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - Pfizer, Inc. (USA) - Sanofi S.A (France) - Shire Plc (UK) - Sunovion Pharmaceuticals, Inc. (USA) - Takeda Pharmaceutical Co., Ltd. (Japan) - Teva Pharmaceutical Industries Ltd. (Israel) - UCB Group (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS & ISSUES 3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 145 (including Divisions/Subsidiaries - 172) - The United States (69) - Canada (11) - Japan (14) - Europe (47) - - France (4) - - Germany (9) - - The United Kingdom (11) - - Italy (1) - - Rest of Europe (22) - Asia-Pacific (Excluding Japan) (23) - Middle East (7) - Africa (1) For more information visit http://www.researchandmarkets.com/research/ht...erapeutics
PFE: 33.99 (unch), LLY: 72.76 (-0.14), BMY: 67.76 (+0.12), GSK: 44.58 (-0.19), ALKS: 59.96 (-0.04), JNJ: 102.46 (+0.16), NBIX: 41.70 (+0.07), SHPG: 255.26 (+0.81), AZN: 68.79 (-0.50), MRK: 60.24 (+0.01), TEVA: 59.98 (-0.25), ABBV: 65.30 (-0.69), NVS: 104.05 (+0.30)
Arena completes two Phase 1 trials for once-daily formulation of Belviq
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:48AM CDT
ARNA: 4.23 (-0.02)
Eisai Realigns U.S. Operations
PR Newswire - Thu Apr 09, 3:30PM CDT
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 25 percent across various U.S. functions. This realignment supports Eisai's desire to create a more efficient and focused organization.
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 102.46 (+0.16), CYCC: 0.80 (-0.01), NVS: 104.05 (+0.30), KPTI: 25.36 (+0.55)
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal
JCN Newswire - Fri Apr 03, 7:33AM CDT
A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that, according to their joint research, the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. These findings were published online in the U.S. academic journal Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring on March 31.
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phwnn8/lennoxgastaut) has announced the addition of the "Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - H. Lundbeck A/S - GW Pharmaceuticals plc - INSYS Therapeutics, Inc. - SymPhar Sp. z.o.o. - ProductLife Group SA - Mylan Inc. - Johnson & Johnson - GlaxoSmithKline plc - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/ph...noxgastaut
JNJ: 102.46 (+0.16), INSY: 59.33 (+0.33), GSK: 44.58 (-0.19)
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 30.53 (-0.19), MRK: 60.24 (+0.01)
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m8gr3t/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - INSYS Therapeutics, Inc. - Eli Lilly and Company - Eisai Co., Ltd. - TransMolecular, Inc. - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Oncolytics Biotech Inc. - Amgen Inc. - Alkermes Plc For more information visit http://www.researchandmarkets.com/research/m8gr3t/recurrent
INSY: 59.33 (+0.33), ONCY: 0.71 (unch), MRK: 60.24 (+0.01), AMGN: 161.74 (-0.62), LLY: 72.76 (-0.14), ALKS: 59.96 (-0.04)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 257.90 (+2.48), CLDX: 25.48 (-0.33), EPZM: 17.17 (-0.26), STML: 13.51 (+0.08), JNJ: 102.46 (+0.16), ABBV: 65.30 (-0.69), INFI: 12.26 (-0.04), PTLA: 36.68 (-0.53), INCY: 107.01 (+0.15), PFE: 33.99 (unch), IMGN: 8.52 (-0.07), AMGN: 161.74 (-0.62), LLY: 72.76 (-0.14), BMY: 67.76 (+0.12), GSK: 44.58 (-0.19), SGEN: 39.69 (-0.25), GILD: 109.64 (+0.34), KITE: 48.89 (-1.13), MRK: 60.24 (+0.01), TEVA: 59.98 (-0.25), CELGZ: 2.60 (-0.10), KPTI: 25.36 (+0.55), NVS: 104.05 (+0.30)
Eisai returns global rights to EZH2 program to Epizyme
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:00AM CDT
EPZM: 17.17 (-0.26)
Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438
Business Wire - Thu Mar 12, 6:00AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that it has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Co. Ltd, or Eisai. Under the terms of the agreement, Epizyme will be solely responsible for global clinical development, manufacturing and commercialization in all countries outside of Japan, where Eisai will retain rights. EPZ-6438, a first-in-class inhibitor of EZH2, is currently being evaluated in a Phase 1/2 clinical study for the treatment of B-cell non-Hodgkin lymphoma (NHL) and INI1-deficient solid tumors, such as synovial sarcoma and malignant rhabdoid tumor.
EPZM: 17.17 (-0.26)
Merck and Eisai team up in cancer
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:51AM CST
MRK: 60.24 (+0.01)
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept
JCN Newswire - Tue Mar 03, 7:56AM CST
Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) (donepezil hydrochloride) has been accepted for review by the Jiangsu Food and Drug Administration in China.
Cognitive Impairment - Pipeline Review, H1 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z64d6n/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Dart NeuroScience LLC - Eisai Co., Ltd. - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Iproteos S.L. - Merck & Co., Inc. - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - Neuralstem, Inc. - Novartis AG - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - Sanofi - Shire Plc - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Upsher-Smith Laboratories, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/z64d6n/cognitive
PFE: 33.99 (unch), LLY: 72.76 (-0.14), BMY: 67.76 (+0.12), AZN: 68.79 (-0.50), MRK: 60.24 (+0.01), SHPG: 255.26 (+0.81), TEVA: 59.98 (-0.25), ABBV: 65.30 (-0.69), CUR: 1.69 (-0.01), NVS: 104.05 (+0.30)
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting
JCN Newswire - Thu May 14, 2:12AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that a series of abstracts highlighting new study results on Halaven (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, "eribulin" and Lenvima (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib" will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015. Medullary Thyroid Cancer Therapeutics Clinical Trials Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 30, 6:31AM CDT
The report "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. Complete report on H1 2015 Clinical Trials review of "Medullary Thyroid Cancer" addiction with 44 market data tables and 109 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/medullary-th...eport.html .
IMMU: 4.15 (+0.03), EXEL: 3.34 (-0.03)
Eisai and Nihon Medi-Physics Enter Collaboration Agreement to Contribute to Diagnosis and Treatment of Dementia with Lewy Bodies
JCN Newswire - Mon Apr 27, 8:32AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, "Eisai"
and Nihon Medi-Physics Co., Ltd. (Headquarters: Tokyo, Representative Director, President: Dr. Yutaka Takeuchi, "Nihon Medi-Physics" announced today that they have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 7.48 (+0.14), FOMX: 11.49 (+0.08), GSK: 44.58 (-0.19), BMY: 67.76 (+0.12), CBPO: 102.28 (+0.72), DERM: 14.90 (-0.07), CCXI: 8.03 (+0.82), ANAC: 61.04 (-1.33), CLTX: 0.55 (unch), CELGZ: 2.60 (-0.10)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 12.57 (-0.09), GSK: 44.58 (-0.19), CELGZ: 2.60 (-0.10)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 12.74 (-0.02), FOMX: 11.49 (+0.08), PVCT: 0.87 (unch), JNJ: 102.46 (+0.16), DERM: 14.90 (-0.07), ANAC: 61.04 (-1.33), XNCR: 15.44 (+0.12), REGN: 488.41 (-0.60), AQXP: 7.48 (+0.14), BMY: 67.76 (+0.12), GSK: 44.58 (-0.19), VRX.TO: 270.02 (+2.67), CBPO: 102.28 (+0.72), MRK: 60.24 (+0.01), CCXI: 8.03 (+0.82), CLTX: 0.55 (unch), CELGZ: 2.60 (-0.10), NVS: 104.05 (+0.30)
CNS Therapeutics - Global Strategic Business Report 2015-2020
M2 - Mon Apr 13, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht282w/cns_therapeutics) has announced the addition of the "CNS Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 145 companies including many key and niche players such as: - AbbVie Inc. (USA) - Actavis Plc. (Ireland) - Alkermes Plc. (Ireland) - Amneal Pharmaceuticals, LLC (USA) - Aspen Pharmacare Holdings Limited (Australia) - AstraZeneca Plc (UK) - BIAL Group (Portugal) - Boehringer Ingelheim GmbH (Germany) - Bristol-Myers Squibb (USA) - Dainippon Sumitomo Pharma Co., Ltd. (Japan) - Eisai Co., Ltd. (Japan) - Eli Lilly and Co. (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fabre-Kramer Pharmaceuticals, Inc. (USA) - GlaxoSmithKline (UK) - H. Lundbeck A/S (Denmark) - Johnson & Johnson (USA) - Janssen Pharmaceuticals, Inc. (USA) - Merck & Co., Inc. (USA) - Neurocrine Biosciences, Inc. (USA) - Novartis AG (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - Pfizer, Inc. (USA) - Sanofi S.A (France) - Shire Plc (UK) - Sunovion Pharmaceuticals, Inc. (USA) - Takeda Pharmaceutical Co., Ltd. (Japan) - Teva Pharmaceutical Industries Ltd. (Israel) - UCB Group (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS & ISSUES 3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 145 (including Divisions/Subsidiaries - 172) - The United States (69) - Canada (11) - Japan (14) - Europe (47) - - France (4) - - Germany (9) - - The United Kingdom (11) - - Italy (1) - - Rest of Europe (22) - Asia-Pacific (Excluding Japan) (23) - Middle East (7) - Africa (1) For more information visit http://www.researchandmarkets.com/research/ht...erapeutics
PFE: 33.99 (unch), LLY: 72.76 (-0.14), BMY: 67.76 (+0.12), GSK: 44.58 (-0.19), ALKS: 59.96 (-0.04), JNJ: 102.46 (+0.16), NBIX: 41.70 (+0.07), SHPG: 255.26 (+0.81), AZN: 68.79 (-0.50), MRK: 60.24 (+0.01), TEVA: 59.98 (-0.25), ABBV: 65.30 (-0.69), NVS: 104.05 (+0.30)
Arena completes two Phase 1 trials for once-daily formulation of Belviq
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:48AM CDT
ARNA: 4.23 (-0.02)
Eisai Realigns U.S. Operations
PR Newswire - Thu Apr 09, 3:30PM CDT
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 25 percent across various U.S. functions. This realignment supports Eisai's desire to create a more efficient and focused organization.
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 102.46 (+0.16), CYCC: 0.80 (-0.01), NVS: 104.05 (+0.30), KPTI: 25.36 (+0.55)
Niigata University and Eisai Present Results of Joint Research in U.S. Academic Journal
JCN Newswire - Fri Apr 03, 7:33AM CDT
A research group led by Professor Takeshi Ikeuchi of the Department of Molecular Genetics within the Brain Research Institute at Niigata University and Eisai Co., Ltd. announced today that, according to their joint research, the amount of plasma desmosterol was found to be highly correlated with longitudinal cognitive decline in patients with Alzheimer's disease. These findings were published online in the U.S. academic journal Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring on March 31.
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phwnn8/lennoxgastaut) has announced the addition of the "Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - H. Lundbeck A/S - GW Pharmaceuticals plc - INSYS Therapeutics, Inc. - SymPhar Sp. z.o.o. - ProductLife Group SA - Mylan Inc. - Johnson & Johnson - GlaxoSmithKline plc - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/ph...noxgastaut
JNJ: 102.46 (+0.16), INSY: 59.33 (+0.33), GSK: 44.58 (-0.19)
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 30.53 (-0.19), MRK: 60.24 (+0.01)
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m8gr3t/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - INSYS Therapeutics, Inc. - Eli Lilly and Company - Eisai Co., Ltd. - TransMolecular, Inc. - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Oncolytics Biotech Inc. - Amgen Inc. - Alkermes Plc For more information visit http://www.researchandmarkets.com/research/m8gr3t/recurrent
INSY: 59.33 (+0.33), ONCY: 0.71 (unch), MRK: 60.24 (+0.01), AMGN: 161.74 (-0.62), LLY: 72.76 (-0.14), ALKS: 59.96 (-0.04)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 257.90 (+2.48), CLDX: 25.48 (-0.33), EPZM: 17.17 (-0.26), STML: 13.51 (+0.08), JNJ: 102.46 (+0.16), ABBV: 65.30 (-0.69), INFI: 12.26 (-0.04), PTLA: 36.68 (-0.53), INCY: 107.01 (+0.15), PFE: 33.99 (unch), IMGN: 8.52 (-0.07), AMGN: 161.74 (-0.62), LLY: 72.76 (-0.14), BMY: 67.76 (+0.12), GSK: 44.58 (-0.19), SGEN: 39.69 (-0.25), GILD: 109.64 (+0.34), KITE: 48.89 (-1.13), MRK: 60.24 (+0.01), TEVA: 59.98 (-0.25), CELGZ: 2.60 (-0.10), KPTI: 25.36 (+0.55), NVS: 104.05 (+0.30)
Eisai returns global rights to EZH2 program to Epizyme
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 8:00AM CDT
EPZM: 17.17 (-0.26)
Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438
Business Wire - Thu Mar 12, 6:00AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that it has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Co. Ltd, or Eisai. Under the terms of the agreement, Epizyme will be solely responsible for global clinical development, manufacturing and commercialization in all countries outside of Japan, where Eisai will retain rights. EPZ-6438, a first-in-class inhibitor of EZH2, is currently being evaluated in a Phase 1/2 clinical study for the treatment of B-cell non-Hodgkin lymphoma (NHL) and INI1-deficient solid tumors, such as synovial sarcoma and malignant rhabdoid tumor.
EPZM: 17.17 (-0.26)
Merck and Eisai team up in cancer
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 6:51AM CST
MRK: 60.24 (+0.01)
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept
JCN Newswire - Tue Mar 03, 7:56AM CST
Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) (donepezil hydrochloride) has been accepted for review by the Jiangsu Food and Drug Administration in China.
